TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39551608

Group type: EXPERIMENTAL
Intervention: Marathon runners
Number of subjects: 129

Group type: COMPARATOR
Intervention: Patients with type 1 MI
Number of subjects: 129
Study: 39551735

Group type: EXPERIMENTAL
Intervention: Three daily assessments of depressive symptoms across one menstrual cycle
Number of subjects: 77
Study: 39551766

Group type: EXPERIMENTAL
Intervention: Chronic Disease Management Test (CDMT) used by intervention PCPs.
Number of subjects: 333

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 333
Study: 39551791

Group type: EXPERIMENTAL
Intervention: HTNV DNA vaccine (2 mg/vaccination)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PUUV DNA vaccine (2 mg/vaccination)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined HTNV/PUUV DNA vaccine (2 mg/vaccination of 1:1 mixture)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HTNV DNA vaccine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PUUV DNA vaccine
Number of subjects: 22
Study: 39551821

Group type: EXPERIMENTAL
Intervention: Conservative surgical approach
Number of subjects: 1
Study: 39551891

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 731
Study: 39552082

Group type: EXPERIMENTAL
Intervention: Virtual Patient Simulation (VPS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: In-Person Simulation (IPS)
Number of subjects: 40
Study: 39552153

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 23
Study: 39552427

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39552592

Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 39552638

Group type: EXPERIMENTAL
Intervention: 2LM niraparib monotherapy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Active surveillance (AS)
Number of subjects: 199
Study: 39552682

Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty (TEA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Distal humeral hemiarthroplasty (HA)
Number of subjects: 13
Study: 39552943

Group type: EXPERIMENTAL
Intervention: Support Group Leader EDucation Program (13-session training via videoconference)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 148
Study: 39553451

Group type: EXPERIMENTAL
Intervention: Social media use
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Screen time (general)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Hostile thoughts
Number of subjects: 4000
Study: 39553845

Group type: EXPERIMENTAL
Intervention: Personalized risk prediction system for mortality
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Personalized risk prediction system for rehospitalization for heart failure
Number of subjects: 965
Study: 39553900

Group type: EXPERIMENTAL
Intervention: LAAO combined with catheter ablation
Number of subjects: 3096

Group type: COMPARATOR
Intervention: LAAO only
Number of subjects: 3096
Study: 39553907

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography-derived fractional flow reserve (FFR)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: High FFR
Number of subjects: 245
Study: 39553909

Group type: EXPERIMENTAL
Intervention: Telemedicine integrated care
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1039
Study: 39554793

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 554
Study: 39554834

Group type: EXPERIMENTAL
Intervention: Metformin plus brief healthy diet and exercise education (MET+LIFE)
Number of subjects: 1637

Group type: COMPARATOR
Intervention: LIFE alone
Number of subjects: 1637
Study: 39555240

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (not specified)
Number of subjects: 0
Study: 39555321

Group type: EXPERIMENTAL
Intervention: AutoPrognosis machine learning model
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Gradient Boosting (GB)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 960
Study: 39555388

Group type: EXPERIMENTAL
Intervention: Prediction algorithm for exacerbations in COPD patients
Number of subjects: 111
Study: 39555632

Group type: COMPARATOR
Intervention: Psychostimulants
Number of subjects: 136
Study: 39555642

Group type: EXPERIMENTAL
Intervention: Laughter yoga (twice a week for 35-40 minutes, six sessions total)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 39555800

Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: MPSV4 priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACYW-TT and MPSV4
Number of subjects: 0
Study: 39555814

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 7062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7062
Study: 39555818

Group type: EXPERIMENTAL
Intervention: Oral infigratinib at 0.25 mg/kg for 18 months (cohort 5)
Number of subjects: 72
Study: 39555820

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 416

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (sotalol or amiodarone)
Number of subjects: 416
Study: 39555823

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 7062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7062
Study: 39555822

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Oral anticoagulation
Number of subjects: 1600
Study: 39555826

Group type: EXPERIMENTAL
Intervention: Tirzepatide (up to 15 mg subcutaneously once per week)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 731
Study: 39555827

Group type: EXPERIMENTAL
Intervention: Intensive treatment targeting systolic blood pressure <120 mm Hg
Number of subjects: 12821

Group type: COMPARATOR
Intervention: Standard treatment targeting systolic blood pressure <140 mm Hg
Number of subjects: 12821

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 12821

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 12821
Study: 39555828

Group type: EXPERIMENTAL
Intervention: Nexiguran ziclumeran (nex-z)
Number of subjects: 36
Study: 39556016

Group type: EXPERIMENTAL
Intervention: RP-A501 infusion with transient immunomodulatory regimen (prednisone, tacrolimus or sirolimus, and rituximab)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: RP-A501 infusion
Number of subjects: 7
Study: 39556124

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 108
Study: 39556192

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 2622

Group type: COMPARATOR
Intervention: Dolutegravir (DTG) + 2 NRTIs
Number of subjects: 2622
Study: 39556238

Group type: EXPERIMENTAL
Intervention: Family Check-Up Online (FCU-O)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 374
Study: 39556379

Group type: EXPERIMENTAL
Intervention: PVI plus EIVOM and linear ablation
Number of subjects: 498

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 498
Study: 39556389

Group type: EXPERIMENTAL
Intervention: gantenerumab
Number of subjects: 1939

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1939
Study: 39556397

Group type: EXPERIMENTAL
Intervention: Baby Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE), 50 hours over 2 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual motor activities (Control)
Number of subjects: 46
Study: 39556768

Group type: EXPERIMENTAL
Intervention: Muvalaplin 10 mg/d
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Muvalaplin 60 mg/d
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Muvalaplin 240 mg/d
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 39556769

Group type: EXPERIMENTAL
Intervention: Zerlasiran 450 mg every 24 weeks for 2 doses
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Zerlasiran 300 mg every 16 weeks for 3 doses
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Zerlasiran 300 mg every 24 weeks for 2 doses
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (subcutaneous dose every 16 weeks for 3 doses or every 24 weeks for 2 doses)
Number of subjects: 178
Study: 39556772

Group type: EXPERIMENTAL
Intervention: Secretin infusion (1 pmol/kg/min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study: 39556810

Group type: EXPERIMENTAL
Intervention: Live With Wearable Monitoring Device program with ongoing professional and peer support (1 home visit and biweekly communication via WhatsApp)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 76
Study: 39556824

Group type: EXPERIMENTAL
Intervention: Sling wear (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified (intervention)
Number of subjects: 0
Study: 39557058

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus ramucirumab (switch maintenance group)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Continuation of FOLFOX or CAPOX (control group)
Number of subjects: 280
Study: 39557109

Group type: EXPERIMENTAL
Intervention: Apixaban + placebo
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: Apixaban + aspirin
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: Warfarin + placebo
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: Warfarin + aspirin
Number of subjects: 4614

Group type: COMPARATOR
Intervention: Apixaban vs. Warfarin
Number of subjects: 4614

Group type: COMPARATOR
Intervention: Aspirin vs. Placebo
Number of subjects: 4614
Study: 39557398

Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Older age, hyperlipidemia, and higher leptin levels
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores
Number of subjects: 164
Study: 39557487

Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg once daily for 24 weeks
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study: 39557547

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioural economic nudge intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 39557549

Group type: EXPERIMENTAL
Intervention: mHealth treatment (audio-only mobile phone)
Number of subjects: 2162

Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 2162
Study: 39557557

Group type: EXPERIMENTAL
Intervention: 150 mg of acetylsalicylic acid daily (LDA)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 39557692

Group type: EXPERIMENTAL
Intervention: Chronic CSC
Number of subjects: 83
Study: 39557730

Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0
Study: 39557997

Group type: EXPERIMENTAL
Intervention: Sleep-wake data combined with prior mood episode history
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Daily circadian phase shifts
Number of subjects: 168
Study: 39558017

Group type: EXPERIMENTAL
Intervention: TN-IBC tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive tumor-infiltrating immune components
Number of subjects: 0

Group type: COMPARATOR
Intervention: TN-non-IBC tumors
Number of subjects: 0
Study: 39558052

Group type: EXPERIMENTAL
Intervention: Structured coordinative exercise programme focusing on locomotor and balance skills (30 min, 2 days a week for 8 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal curriculum (Control group)
Number of subjects: 41
Study: 39558214

Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support interventions targeting male partners via social events, home visits, and printed materials
Number of subjects: 408

Group type: COMPARATOR
Intervention: Existing routine care
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support interventions targeting male partners
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 408
Study: 39558280

Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (G-ANC)
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Individual Antenatal Care (I-ANC)
Number of subjects: 1761
Study: 39558302

Group type: EXPERIMENTAL
Intervention: Daily assessments via the patientMpower app including handheld spirometry and exercise tests.
Number of subjects: 350
Study: 39558330

Group type: EXPERIMENTAL
Intervention: First-contact physiotherapy (FCP) model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual family physician (FP) care
Number of subjects: 60
Study: 39558366

Group type: EXPERIMENTAL
Intervention: Mixed-reality (MixR) visualization during patient setup for 5 fractions of RT.
Number of subjects: 18

Group type: COMPARATOR
Intervention: 3-point alignment during patient setup for 5 fractions of RT.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mixed-reality (MixR) visualization and 3-point alignment.
Number of subjects: 18
Study: 39558368

Group type: EXPERIMENTAL
Intervention: Permissive Weight Bearing (PWB)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Restricted Weight Bearing (RWB)
Number of subjects: 115
Study: 39558377

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) activated during intervention period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (CDSS deactivated) during control period
Number of subjects: 0
Study: 39558411

Group type: EXPERIMENTAL
Intervention: JIA group (self-reported physical health assessed with CHQ)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: JIA group (self-reported psychosocial health assessed with CHQ)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: JIA group (self-reported physical disability assessed with CHAQ)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Poor physical health (CHQ PhS < 40)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Disease-related pain
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Patient's global assessment of disease impact on wellbeing
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Active disease according to Wallace
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Physician-reported global assessment of disease activity
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (matched population-based controls)
Number of subjects: 221
Study: 39558601

Group type: EXPERIMENTAL
Intervention: Withdrawal of analgesics
Number of subjects: 21
Study: 39558828

Group type: EXPERIMENTAL
Intervention: Centralized medical monitoring of local radiological/functional imaging reports
Number of subjects: 640

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 640
Study: 39558901

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2-3 mg/day (flexible dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39559133

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal resection Turbinoplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Partial inferior turbinectomy
Number of subjects: 40
Study: 39559450

Group type: EXPERIMENTAL
Intervention: Total number of comorbidities
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Low body mass index
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: 3, 4 or >5 comorbidities
Number of subjects: 830
Study: 39559491

Group type: EXPERIMENTAL
Intervention: RegEx algorithm for patient identification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual review
Number of subjects: 0
Study: 39559532

Group type: EXPERIMENTAL
Intervention: Flexible ureteroscopy with a tip-bendable suction ureteral access sheath (f-URS with S-UAS)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Mini-percutaneous nephrolithotomy (mPCNL)
Number of subjects: 720
Study: 39559856

Group type: EXPERIMENTAL
Intervention: EMBOTRAP device
Number of subjects: 997
Study: 39559990

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39560075

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (high-dose greater than 1000 mg/day)
Number of subjects: 16325
Study: 39560363

Group type: EXPERIMENTAL
Intervention: mLab App
Number of subjects: 525

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 525
Study: 39560398

Group type: EXPERIMENTAL
Intervention: CIH therapies (n = 140)
Number of subjects: 280

Group type: COMPARATOR
Intervention: SRC (n = 140)
Number of subjects: 280
Study: 39560548

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of PG201 (405.4 mg) and celecoxib (100 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Individual formulations of PG201 and celecoxib
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of PG201 and celecoxib
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both FDC and individual formulations
Number of subjects: 46
Study: 39560745

Group type: EXPERIMENTAL
Intervention: Simplified meal announcement (SMA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Carbohydrate counting (CC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SMA
Number of subjects: 46

Group type: COMPARATOR
Intervention: CC
Number of subjects: 46
Study: 39560771

Group type: EXPERIMENTAL
Intervention: Prophylactic dose of enoxaparin starting at 0.5 mg/kg adjusted to anti-Xa range of 0.2-0.5 IU/mL for older children
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Therapeutic dose of enoxaparin starting at 1.5 mg/kg adjusted to anti-Xa range of greater than 0.5-1.0 IU/mL or 0.2-0.5 IU/mL for infants
Number of subjects: 258

Group type: COMPARATOR
Intervention: Usual care (no enoxaparin)
Number of subjects: 258
Study: 39560777

Group type: COMPARATOR
Intervention: 2021
Number of subjects: 72242

Group type: COMPARATOR
Intervention: 2022
Number of subjects: 72242
Study: 39560860

Group type: EXPERIMENTAL
Intervention: Osseodensification technique
Number of subjects: 32
Study: 39560862

Group type: EXPERIMENTAL
Intervention: Adavosertib (150 mg bid for 3 days on/4 days off) plus Durvalumab (1500 mg Q4W)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adavosertib (300 mg qd for 5 days on/2 days off) plus Durvalumab (1500 mg Q4W)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adavosertib plus Durvalumab
Number of subjects: 55
Study: 39560984

Group type: EXPERIMENTAL
Intervention: Culturally tailored, in-language Diabetes Prevention Program (DPP) videos (2-3 per week for 12 weeks) and biweekly phone calls from bilingual staff, plus produce for 10 weeks from a community-supported agriculture program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 150
Study: 39561129

Group type: EXPERIMENTAL
Intervention: Call for Life-Interactive Voice Response with standard of care
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 206
Study: 39561184

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (ALB)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Albendazole/ivermectin (ALB/IVM) combinations
Number of subjects: 94

Group type: COMPARATOR
Intervention: Kato-Katz (K-K)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 94
Study: 39561225

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg biweekly in addition to high-intensity statins
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo in addition to high-intensity statins
Number of subjects: 300
Study: 39561235

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 849

Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Shock in last 90 days
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Overall quality of life
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator shocks
Number of subjects: 849
Study: 39561281

Group type: EXPERIMENTAL
Intervention: dVHH NS7CAR-T cells (dosage levels: 5×10^5/kg and 1×10^6/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: dVHH NS7CAR-T cells
Number of subjects: 10
Study: 39561359

Group type: EXPERIMENTAL
Intervention: AI predictive tool using recurrent neural networks (RNN)
Number of subjects: 6125

Group type: EXPERIMENTAL
Intervention: AI predictive tool using light gradient boosting machine (LightGBM)
Number of subjects: 6125

Group type: EXPERIMENTAL
Intervention: AI predictive tool
Number of subjects: 6125

Group type: EXPERIMENTAL
Intervention: Key predictive features
Number of subjects: 6125
Study: 39561384

Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin reverse thermal gel)
Number of subjects: 71
Study: 39561465

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 192
Study: 39561689

Group type: EXPERIMENTAL
Intervention: PS-enriched soy milk (2 g/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal soy milk (control group)
Number of subjects: 13
Study: 39561769

Group type: EXPERIMENTAL
Intervention: Heterozygous LEPR variants
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Exome data from 200,000 individuals in the UK Biobank
Number of subjects: 10000
Study: 39561881

Group type: EXPERIMENTAL
Intervention: Azvudine
Number of subjects: 5735

Group type: COMPARATOR
Intervention: Control
Number of subjects: 5735
Study: 39562048

Group type: EXPERIMENTAL
Intervention: Blood-based assay for EAC and BE using six miRNAs (miR-106b, miR-146a, miR-15a, miR-18a, miR-21, miR-93)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-disease controls
Number of subjects: 0
Study: 39562051

Group type: EXPERIMENTAL
Intervention: Diabetes education and motivational interviewing program based on the IMB model for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60